Table 1 Characteristics of studies included in the review.
Study | Country | Sample size | Inclusion period | Stroke type | Blood collection | Copeptin detection method | Age, y. | Females, % | Stroke severity | Time of death | Death, % | Unfavorable outcome, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Katan M | Western | 359 | 2006–2007 | Ischemic | <72 h | immunoassay(B.R.A.H.M.S) | 75 (63–83) | 41 | 5 (2–10)* | 3 mo. | 12 | 42 |
Zweifel C | Western | 40 | 2006–2007 | Hemorrhagic | <72 h | immunoassay(B.R.A.H.M.S) | 71 (64–78) | 45 | 14 (13–15)** | 1 mo. | 15 | 55 |
Dong XQ | China | 86 | 2006–2008 | Hemorrhagic | <24 h | ELISA(Cusabio) | 65 (42–80) | 23.3 | 8 (5–13)** | 1 wk. | 37.2 | — |
Zhang X | China | 89 | 2007–2009 | Hemorrhagic | <24 h | immunoassay(B.R.A.H.M.S) | 65 (41–79) | 39.3 | 21 (6–31)* | 1 y. | 42.7 | 62.9 |
Zhang JL | China | 245 | 2007–2010 | Ischemic | <72 h | immunoassay(B.R.A.H.M.S) | 73 (64–82) | 42 | 6 (3–12)* | 1 y. | 16.7 | 40.4 |
Zhu XD | China | 303 | 2008–2010 | Hemorrhagic | <24 h | ELISA(Cusabio) | 43.9 ± 12.4 | 56.7 | 2.3 ± 1.2*** | 1 y. | 13.9 | 29.7 |
De Marchis | Western | 783 | 2009–2011 | Ischemic | <24 h | immunoassay(B.R.A.H.M.S) | 71 (60–80) | 38.1 | 6 (3–13)* | 3 mo. | 15.1 | 38.3 |
Dong X | China | 125 | 2010–2011 | Ischemic | <48 h | immunoassay(B.R.A.H.M.S) | 69 (61–85) | 44.8 | 7 (3–12)* | 3 mo. | 14.4 | 32.8 |
Fung C | Western | 18 | 2010–2011 | Hemorrhagic | Adm. | immunoassay(B.R.A.H.M.S) | 57 (48–67) | 66.6 | — | 6 mo. | 22.2 | 27.7 |
Tu WJ | China | 189 | 2010–2012 | Ischemic | <48 h | immunoassay(B.R.A.H.M.S) | 66 (58–75) | 38.1 | 7 (5–12)* | 3 mo. | 13.2 | 38.1 |
Wei ZJ | China | 271 | 2010–2012 | Hemorrhagic | <24 h | ELISA(Cusabio) | 69 (59–81) | 46.9 | 11 (7–15)** | 3 mo. | 12.5 | 30.3 |
Yu WH | China | 118 | 2010–2013 | Hemorrhagic | <6 h | ELISA(Phoenix pharm) | 64 (48–79) | 39 | 15 (5–23)* | 6 mo. | 31.4 | 57.6 |
Zhang A | China | 120 | 2013 | Hemorrhagic | Adm. | ELISA(Phoenix pharm) | 60 (32–84) | 37 | 10.6 ± 4.6** | 3 mo. | 20 | 60 |
